Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies by Bernardo, Miquel et al.
ORIGINAL RESEARCH
Real-WorldData on the Adverse Metabolic Effects
of Second-Generation Antipsychotics and Their
Potential Determinants in Adult Patients: A Systematic
Review of Population-Based Studies
Miquel Bernardo . Fernando Rico-Villademoros . Clemente Garcı́a-Rizo .
Rosa Rojo . Ricardo Gómez-Huelgas
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ABSTRACT
Introduction: To assess the risk of occurrence
and potential determinants of metabolic disor-
ders in adult patients treated with second-gen-
eration antipsychotics (SGAs) under real-world
practice conditions.
Methods: MEDLINE, EMBASE, and PsycInfo
were searched in July 2019 from database
inception. We included population-based, lon-
gitudinal, comparative studies that report the
results of the outcomes of interest for adult
participants, including diabetes, ketoacidosis,
hyperosmolar hyperglycemic state, weight gain/
obesity, dyslipidemia, hypertension, and meta-
bolic syndrome. Two reviewers independently
extracted data on the study design, study qual-
ity, and study outcomes.
Results: We included 40 studies. Most studies
showed that clozapine and olanzapine were
associated with an increased likelihood of
developing diabetes, while the results for
risperidone and quetiapine were mixed.
Although less well studied, ziprasidone and
aripiprazole appeared to not be associated with
the occurrence of diabetes. Information on
antipsychotic-induced weight gain/obesity is
extremely scarce. Regarding dyslipidemia, arip-
iprazole was not associated with an increased
likelihood of developing dyslipidemia, clozap-
ine was associated with an increased likelihood
of developing dyslipidemia, and risperidone,
olanzapine, quetiapine, and ziprasidone
showed mixed results. Two studies suggested an
association between ziprasidone and the
occurrence of hypertension. Several studies
found that the occurrence of a metabolic dis-
order acted as a risk factor for the development
of other metabolic disorders. We did not find
information on brexpiprazole, cariprazine, or
lurasidone, and data on any long-acting SGA
were lacking.
Conclusion: Although there are relevant dif-
ferences among SGAs concerning the risk of
metabolic disorders, it appears that none of the
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SGAs included in our review are fully devoid of
these disturbances.
PLAIN LANGUAGE SUMMARY
Patients with severe mental disorders often
present metabolic disorders such as obesity,
increased blood pressure, high blood sugar, and
abnormal cholesterol or triglyceride levels.
Treatment with antipsychotics may contribute
to the occurrence of these disorders. Using a
systematic review, we have evaluated the risk of
occurrence of these metabolic disorders associ-
ated with the most frequently used antipsy-
chotics—the so-called second-generation
antipsychotics (SGAs)—and which factors
increase the patient chances of presenting a
metabolic disorder when they are treated with
these drugs under routine clinical practice. After
reviewing 40 studies, we found that, although
there are relevant differences among SGAs
concerning the risk of metabolic disorders, it
appears that none of the drugs included in our
review are fully free of these disturbances.
Among the factors that increase the chances of
these disturbances, we highlight that the pres-
ence of a particular metabolic disorder (e.g.,
increased blood pressure) acts as a risk factor for
the occurrence of other metabolic disorders
(e.g., high blood sugar), and that the duration
of treatment could be a relevant factor for the
occurrence of these disorders. Finally, we also
found important gaps in our knowledge about
this matter, mainly the limited information on
the SGAs apparently associated with lower risk
of metabolic disorders in experimental studies
(that is, few studies evaluating ziprasidone and
aripiprazole, and none evaluating brexpipra-
zole, cariprazine, or lurasidone) and the lack of
information on long-acting injectable (that is,




state; Hypertension; Ketoacidosis; Metabolic
syndrome; Obesity; Weight gain
Key Summary Points
Why carry out this study?
Information on antipsychotic-associated
metabolic disorders is derived from short-
term (i.e., 6 weeks) randomized clinical
trials—or systematic reviews of these
trials—conducted in selected populations
devoid of relevant medical or psychiatric
comorbidities that received limited
concomitant medications
Information from patients treated under
real-world conditions for longer time
would be useful for better delineating the
risk of antipsychotic-associated metabolic
disorders and their potential determinants
This systematic review of population-
based case–control and cohort studies
aimed to assess the risk of occurrence and
potential determinants of metabolic
disorders in adult patients treated with
second-generation antipsychotics (SGAs)
under real-world practice conditions
What was learned from the study?
Although there are relevant differences
among SGAs concerning the risk of
metabolic disorders, it appears that none of
the SGAs included in our review are fully
devoid of these disturbances and there are
important gaps in the literature, mainly the
limited informationontheSGAsapparently
associatedwithbettermetabolicprofile (i.e.,
few studies evaluating ziprasidone and
aripiprazole, and none evaluating
brexpiprazole, cariprazine, or lurasidone)
and the lack of population-based studies on
long-acting injectable SGAs
Among potential determinants of these
disturbances, we highlight because of their
clinical implications that the presence of a
particular metabolic disorder acts as a risk
factor for theoccurrenceof othermetabolic
disorders, and the length of antipsychotic
exposure could be a relevant factor for the
occurrence of these disorders
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DIGITAL FEATURES
This article is published with digital features,
including a summary slide and plain language
summary, to facilitate understanding of the




Metabolic disorders, frequently grouped as the
so-called metabolic syndrome (i.e., the co-oc-
currence of abdominal obesity, hyperglycemia,
hypertension, and hyperlipidemia), are com-
mon in patients with severe mental disorders
[1–5] and play a determinant role in the
increased risk of premature mortality, predom-
inantly due to cardiovascular diseases, in psy-
chiatric patients [6].
Treatment with antipsychotics may con-
tribute to the occurrence of metabolic syn-
drome, and thus, clinical practice guidelines
recommend initial physical and laboratory
assessments and periodic follow-up after initi-
ating antipsychotic treatment for the preven-
tion, early recognition, and treatment of these
metabolic disturbances [7]. Results from ran-
domized clinical trials (RCTs) show that there
are marked differences among antipsychotics in
regard to their risks of inducing metabolic dis-
orders [8]. However, this information is derived
from short-term (i.e., 6 weeks) studies con-
ducted in selected populations devoid of rele-
vant medical or psychiatric comorbidities that
received limited concomitant medications.
Therefore, information from patients treated
under real-world conditions for longer time
would be useful for better delineating the risk of
antipsychotic-associated metabolic disorders.
A systematic review on this topic has been
published [9]. However, this otherwise inter-
esting review is limited by the exclusion of
studies conducted in subpopulations, such as
studies conducted in patients with schizophre-
nia, patients with bipolar disorder, or hospital-
based studies, and did not include information
on the potential moderators of the risk of
metabolic disorders. The review included
studies published only until July 2015, a time
frame that limits information on most recently
marketed antipsychotics (e.g., antipsychotics
with apparently good metabolic profiles
according to pivotal trials, such as brexpipra-
zole, cariprazine, and lurasidone [8], which
obtained US Food and Drug Administration
approval in 2015 or later). Antipsychotic treat-
ment selection should be individualized and
based on effectiveness and tolerability in addi-
tion to patients’ preferences. Increasing knowl-
edge of the tolerability profile of well-
established antipsychotics as well as recently
introduced antipsychotics will help achieve
individualized antipsychotic treatment selec-
tion [10].
The objectives of this systematic review were
to assess the risk of occurrence and potential
determinants of diabetes or acute diabetes-re-
lated complications, weight gain/obesity,
hyperlipidemia, hypertension, or metabolic
syndrome in adult patients treated with second-





We focused on real-world population-based
studies. We included longitudinal comparative
studies (i.e., cohort or case–control studies)
since cross-sectional studies do not allow for the
establishment of a causal relationship.
Types of Participants
The studies needed to include or separately
report the results of the outcomes of interest for
adult participants aged 18 years and older. We
did not focus on any specific diagnosis; how-
ever, to be included, studies had to be con-
ducted in patients with a psychiatric diagnosis,
or the psychiatric diagnosis had been included
in the multivariate statistical model. The reason
for this criterion is that the psychiatric diagno-
sis may have an independent impact on the risk
of metabolic disorders [11].
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Types of Interventions
Our interventions of interest were the following
SGAs: amisulpride, aripiprazole, asenapine,
brexpiprazole, cariprazine, clozapine, iloperi-
done, lurasidone, olanzapine, paliperidone,
quetiapine, risperidone, sertindole, ziprasidone,
and zotepine. We included studies reporting
data for individual drugs or for grouped SGAs.
Information on first-generation antipsychotics
(FGAs) was only sought as a comparator to the
SGAs. We had no limitations regarding
comparators.
Types of Outcome Measures
The outcomes of interest of the studies were
diabetes, ketoacidosis, hyperosmolar hyper-
glycemic state, weight gain/overweight/obesity,
dyslipidemia (hyperlipidemia) or the specific
entities hypercholesterolemia or hypertriglyc-
eridemia, hypertension, and metabolic syn-
drome. We accepted and recorded any
definition of these clinical entities, including
diagnoses based on any code system (e.g., ICD-
10) and on exposure to specific treatments (e.g.,
antihypertensives). We excluded studies con-
ducted on pregnant women.
To be included in this review, articles needed
to report the results of at least one of the out-
comes of interest.
Search Methods for Study Identification
The following databases were searched in July
2019 from inception by a medical information
specialist (IS-A, see the Acknowledgments):
MEDLINE, EMBASE, and PsycInfo. The search
strategy is presented in Supplementary Table 1.
Study Selection
A reviewer with a background in research
methodology (FR-V) determined the eligibility
of studies by reading the title/abstract of each
study identified by the search. The reviewer
discarded studies that clearly did not satisfy the
inclusion criteria, and complete copies of the
remaining studies were obtained. The reviewer
assessed all the initially selected complete arti-
cles and selected the papers that met the
previously described eligibility criteria; doubts
regarding whether an article met the criteria
were solved by consensus with a second
reviewer (RR). If no agreement could be
reached, then a third reviewer (MB) was
involved in the assessment.
We did not anonymize the studies prior to
the assessment.
Data Extraction and Management
Two reviewers (FR-V and RR) independently
extracted data from half of the studies, each
using a standard Microsoft Excel form. Both
reviewers cross-checked the data extracted by
the other reviewer with the source article. In
cases of discrepancies, both reviewers discussed
the specific difference to reach an agreement
prior to entering data into the final tables. If no
agreement could be reached, then a third
reviewer (MB) was involved in the assessment.
As characteristics of the studies, we recorded
information on the first author, year of publi-
cation, journal, study design, country, database,
time frame, age as a selection criterion or as the
mean/median, diagnosis and the tool used to
make the diagnosis, type of exposure and its
definition, type of control, outcomes evaluated
and definition, multivariate model used in sta-
tistical analysis and the covariates included in
the model, whether the study used propensity
scores either for matching and/or adjusting for,
and funding source.
After extracting the results of the studies, we
recorded information on the size of the source
population, length of treatment, duration of the
follow-up, outcome evaluated, type of exposure,
sample size of exposed/nonexposed or
case/controls, summary statistic (e.g., percent-
age, incidence rate), type effect measure (i.e.,
odds ratio [OR], relative risk [RR], or hazard ratio
[HR]), point estimate and 95% confidence
interval (CI) of the effect measure, p value, and
point estimates and 95% CI of the effect mea-
sures of the other potential determinants of the
occurrence of metabolic disorders in a table.
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Assessment of Study Quality
The quality of the studies was evaluated by two
reviewers (FR-V and RR) using the New-
castle–Ottawa scale, a widely used tool for
evaluating the quality of nonrandomized stud-
ies in systematic reviews [12]. The New-
castle–Ottawa scale considers three dimensions
in the evaluation by using a ‘‘star system’’: the
selection of study groups (maximum 4 stars);
the comparability of the groups (maximum 2
stars); and the ascertainment of either the
exposure or outcome of interest for case–control
or cohort studies, respectively (maximum 3
stars). To evaluate comparability, we decided to
allocate one star if the study used propensity
scores for matching and/or adjusting in the
statistical analyses; a second star was allocated if
the study explicitly reported controlling for age
and gender, either by matching or adjusting in
the multivariate model.
Following the same criteria used by other
authors [13], a ‘‘poor’’ quality score was reflected
as 0 or 1 star(s) in selection, 0 stars in compa-
rability, or 0 or 1 star(s) in outcomes.
Data Synthesis
Because substantial heterogeneity was expected,
no quantitative synthesis was expected to be
carried out. The results of individual studies are
presented using forest plots for descriptive pur-
poses. Since they require a different interpreta-
tion, forest plots are presented separately for
odds ratios/relative risks (for binary outcomes)
and hazard ratios (for time-to-event outcomes).
When reported in the same forest plot, odds
ratios and relative risks are clearly identified.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
RESULTS
Study Selection
Finally, 40 studies published between 2001 and
2019 were included in this review. The flow
chart of the study selection process is presented
in Fig. 1.
Study Characteristics
A description of the main characteristics of the
studies included in this review is presented in
Supplementary Table 2. Twenty-six (65.0%) of
the studies had a retrospective cohort design
and 14 (35.0%) were case–control studies. Five
(12.5%) studies employed a propensity score
methodology, three using matching and two
using propensity scores for adjustment in the
statistical analysis. Most of the studies were
conducted in North America, 24 in the USA and
5 in Canada; 5 studies were conducted in Tai-
wan; 5 studies were in Europe; and 1 study used
databases from the UK and Canada. Nineteen of
the studies were partially or fully supported by a
pharmaceutical company (12 studies were sup-
ported by the comarketer of aripiprazole), 14
received noncommercial support, 6 did not
report the funding source, and 1 did not receive
any support.
Six (15.0%) studies included subjects aged 65
or older. Fourteen (35.0%) studies included
patients with schizophrenia, three (7.5%)
patients with bipolar disorder, and two (5.0%)
patients with depression, and the remaining
studies included patients with a variety of
diagnoses. The antipsychotics most commonly
studied were olanzapine (n = 26, 65.0%),
risperidone (n = 21, 52.5%), quetiapine (n = 20,
50.0%), and clozapine (n = 15, 37.5%), while
the less commonly studied antipsychotics were
ziprasidone (n = 7, 17.5%) and aripiprazole
(n = 5, 12.5%). We did not find any studies that
evaluated any other SGAs under study (namely,
amisulpride, asenapine, brexpiprazole, car-
iprazine, iloperidone, lurasidone, paliperidone,
sertindole, or zotepine) or data on any long-
acting SGA. The most common comparators
were FGA (n = 17, 42.5%) and patients not
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receiving antipsychotics (n = 13, 32.5%). Three
studies provided a comparison of the various
SGAs. Two studies were conducted with
antipsychotic-naı̈ve patients as a comparator,
and another study used the general population.
Regarding outcomes, diabetes (n = 32, 80%) was
the most commonly studied, followed by dys-
lipidemia (n = 9, 22.3%), hypertension (n = 7,
17.5%), hyperglycemia/ketoacidosis (n = 4,
10.0%), and weight gain/obesity (n = 3, 7.5%);
we did not find any study reporting the risk of
occurrence of metabolic syndrome as a whole.
Risk of Bias Within Studies
The evaluation of the quality of the studies
using the Newcastle–Ottawa scale is presented
in Supplementary Table 3 for the cohort studies
and in Supplementary Table 4 for the
case–control studies. Six (23.1%) of the 26
cohort studies and 1 (7.1%) case–control study
had at least one dimension categorized as poor
quality.
Results of Individual Studies
Studies Conducted in Adults
Diabetes The results of the studies comparing
the risk of occurrence of diabetes with individ-
ual antipsychotics compared to subjects who
did not receive antipsychotics are presented in
Fig. 2a. Two studies showed that clozapine is
associated with an increased likelihood of
occurrence of diabetes, with heterogeneous
Fig. 1 Flow diagram study selection
Adv Ther
results [14, 15] . Five studies evaluated the risk
of diabetes in patients treated with risperidone
or olanzapine compared to subjects who did not
receive antipsychotics [14–18]. Risperidone was
not associated with the occurrence of diabetes
[14–18], except in one study that showed that a
high dose (i.e., a dose within the top third of the
daily dose range for the specific subgroup) was
associated with the occurrence of diabetes (OR
1.68, 95% CI 1.07–2.65) [16]. With heteroge-
neous results regarding the strength of the
association, olanzapine was consistently asso-
ciated with an increased likelihood of diabetes
[14–18]; in one study, the higher the dose, the
greater the likelihood of developing diabetes
with olanzapine [16]. Compared with subjects
Fig. 2 a Risk of diabetes in adults who received second-
generation antipsychotics compared to subjects who did
not receive antipsychotics (binary outcome). aIn Gian-
francesco et al. [16] low, medium, and high dose
corresponded to the bottom, middle, and top third of
the daily dose range for each patient subgroup within each
antipsychotic category. b Risk of diabetes in adults who
received second-generation antipsychotics compared to
subjects who did not receive antipsychotics (time-to-event
outcome). Results are reported for young adults (i.e.,
18–29 years) with low exposure (30–179 cumulative
defined daily dose [cDDDs]), medium exposure
(180–364 cDDDs), and high exposure (at least 365
cDDDs) compared to subjects who did not receive
antipsychotics (exposure less than 30 cDDDs). APS
antipsychotic, CI confidence interval, Clo clozapine, HR
hazard ratio, Ola olanzapine, OR odds ratio, Que queti-
apine, Ris risperidone, SGAs second-generation antipsy-
chotics, Zip ziprasidone
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who did not receive antipsychotics, quetiapine
was not associated with the occurrence of dia-
betes [15–17], regardless of the dose [16]. A
single study evaluating ziprasidone did not find
an association with the occurrence of diabetes.
Compared to subjects who did not receive an
antipsychotic, SGAs as a whole were associated
with an increased likelihood of diabetes [19]
(Fig. 2a), and the likelihood increased as expo-
sure increased [20] (Fig. 2b).
The results of the comparisons of SGAs with
FGAs are presented in Fig. 3a for binary out-
comes and Fig. 3b for time-to-event outcomes.
Seven studies reported binary outcomes
[11, 18, 21–25], showing a lack of association
with the occurrence of diabetes for risperidone
and quetiapine compared to FGA and mixed
results for clozapine and olanzapine (Fig. 3a). A
study showed no apparent dose–response asso-
ciation between exposure to low, medium, and
high doses of clozapine, risperidone, and que-
tiapine [24]; low doses of olanzapine were not
associated with an increased likelihood of
developing diabetes (OR 1.10, 95% CI
0.90–1.50), while medium (OR 1.60, 95% CI
1.30–1.90) and high doses (OR 1.50, 95% CI
1.20–1.80) were associated with an increased
likelihood of developing diabetes [24]. Com-
parisons with FGAs using time-to-event out-
comes (Fig. 3b) [26–31] showed mixed results
for clozapine, risperidone, and quetiapine,
while the results for ziprasidone from three
studies showed no significantly increased like-
lihood of developing diabetes; of the six studies,
five showed an association between exposure to
olanzapine and the likelihood of developing
diabetes with heterogeneous results regarding
the strength of the association (the HR varied
from 1.15 to 3.66).
Three studies provided head-to-head com-
parisons among SGAs and two of them using
time-to-event outcomes showed no difference
among them for the risk of developing diabetes
(Supplementary Fig. 1a) [32, 33], while a study
using a binary outcome showed a 20% increased
likelihood of the occurrence of diabetes in
olanzapine-treated patients compared to those
treated with risperidone (OR 1.20, 95% CI
1.00–1.43) [34] (Supplementary Fig. 1b). Studies
of the risk of developing diabetes in those who
received SGAs using comparators other than
not receiving antipsychotics, FGAs, or head-to-
head comparisons are presented in Supple-
mentary Fig. 2 for binary outcomes and Sup-
plementary Fig. 3 for time-to-event outcomes
[35–40]. Among these latter studies, Rajkumar
et al. [39], in young adults with schizophrenia,
showed that the three individual antipsychotics
analyzed, namely, clozapine, olanzapine, and
aripiprazole, were associated with a significantly
increased likelihood of developing diabetes
compared with antipsychotic-naı̈ve patients.
Nielsen et al. [38] also used antipsychotic-naı̈ve
patients as comparators and reported an
increased likelihood of developing diabetes for
clozapine and olanzapine but a reduced likeli-
hood of developing diabetes for aripiprazole;
they reported no association for risperidone,
quetiapine, and ziprasidone.
Diabetes-Related Complications Two studies
evaluated the risk of developing diabetes-related
complications, such as hyperglycemia crisis,
ketoacidosis, and a hyperosmolar hyper-
glycemic state [29, 41]. One of the studies
excluded patients with a previous diagnosis of
diabetes [29]. The other study did not exclude
patients with diabetes, but most patients did
not have a diagnosis of diabetes [41]. These
studies showed an increased likelihood of these
complications with clozapine (HR 3.75, 95% CI
cFig. 3 a Risk of diabetes in adults who received second-
generation antipsychotics compared to those who received
first-generation antipsychotics (binary outcome). Lambert
et al. [24] defined alow dose as\ 7.5 mg for olanzap-
ine,\ 3 mg for risperidone,\ 300 mg for clozapine,
and\ 250 for quetiapine; bmedium dose as 7.5–12.5 mg
for olanzapine, 3–6 mg for risperidone; 300–600 mg for
clozapine; and 250–500 mg for quetiapine; and chigh dose
as\ 12.5 mg for olanzapine,[ 6 mg for risperi-
done,[ 600 mg for clozapine, and[ 500 mg for queti-
apine. b Risk of diabetes in adults who received second-
generation antipsychotics compared to those who received
first-generation antipsychotics (time-to-event outcomes).
Ari aripiprazole, CI confidence interval, Clo clozapine,
FGAs first-generation antipsychotics, HR hazard ratio, Ola
olanzapine, OR odds ratio, Que quetiapine, Ris risperidone,
RR relative risk, Zip ziprasidone
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1.39–10.09) and olanzapine (HR 1.77, 95% CI
1.05–2.98) compared to FGAs and no difference
between olanzapine and risperidone or between
quetiapine and risperidone in this regard
(Fig. 4).
Obesity and Weight Gain We found a single
study that evaluated the risk of occurrence of
obesity with SGAs, reporting that, compared to
FGAs, risperidone, quetiapine, ziprasidone, and
aripiprazole were not associated with the
occurrence of obesity (the effect sizes were not
reported), while olanzapine was associated with
a reduced likelihood of occurrence of obesity
(OR 0.60, 95% CI 0.36–1.00) [42].
Two studies reported the risk of weight gain
with olanzapine and risperidone compared to
the risk with FGAs [23] (Supplementary Fig. 4)
and the risk with olanzapine and quetiapine
compared to lithium [35] (Supplementary
Fig. 5). All three SGAs were associated with an
increased likelihood of weight gain compared
with the controls.
Dyslipidemia Seven studies reported the risk
of developing dyslipidemia with SGAs in adults
(Fig. 5a, b) [11, 36, 40, 43–46]. The results of two
studies indicated that aripiprazole was not
associated with an increased likelihood of
developing dyslipidemia, while clozapine was
consistently associated with the occurrence of
dyslipidemia in three studies. Risperidone,
olanzapine, quetiapine, and ziprasidone
showed mixed results. Overall, SGAs were asso-
ciated with an increased risk of developing
dyslipidemia compared to patients without
schizophrenia [36] and the general population
[43] but not compared to FGAs [43, 46].
Hypertension The results of the six studies
that evaluated the potential association
between treatment with SGAs and the risk of
hypertension [11, 35, 36, 42, 46, 47] are pre-
sented in Fig. 6a, b. Two studies conducted by
the same research group reported an increased
risk of occurrence of hypertension with
ziprasidone compared to FGAs; in those studies,
the authors reported no association with
hypertension for risperidone, olanzapine, que-
tiapine, and aripiprazole [42, 46]. In another
study, compared with lithium, olanzapine was
associated with a higher likelihood of develop-
ing hypertension, but quetiapine was not [35].
Studies Conducted in Patients Aged 65 Years
or Older
In this review, six studies were conducted
specifically in patients aged 65 years or older
[25, 48–52], and one study reported separate
results for patients within this age stratum [41].
The results regarding the risk of occurrence of
diabetes are mixed but consistently show that
SGAs as a whole are associated with an
Fig. 4 Risk of hyperglycemia-related complications in
individuals who received second-generation antipsychotics
(time-to-event outcomes). CI confidence interval, Clo
clozapine, FGAs first-generation antipsychotics, HR hazard
ratio, Ola olanzapine, Que quetiapine, Ris risperidone.
aHyperglycemia was defined as the first hospital admission
in the 365 days following drug initiation that was
associated with a preadmission diagnosis of hyperglycemia,
diabetic ketoacidosis, or a hyperglycemic hyperosmolar
state based on ICD-9 and ICD-10 diagnostic codes
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increased likelihood of occurrence of diabetes-
related complications (Fig. 7). One study evalu-
ated the head-to-head risk of metabolic disor-
ders in this population [41], showing that
quetiapine was associated with a lower likeli-
hood of developing diabetes-related complica-
tions than risperidone (HR 0.69, 95% CI
0.53–0.90), and olanzapine and risperidone did
not differ in terms of the risk of developing
diabetes-related complications (HR 1.13, 95%
CI 0.87–1.48) (Fig. 8).
Polypharmacy with Antipsychotics
Nine studies explicitly stated that they took into
consideration the use of a combination of
antipsychotics and five of them reported speci-
fic results for that subgroup (Supplementary
Table 1). Citrome et al. found that, compared to
FGAs, the use of two or more SGAs was associ-
ated with an increased likelihood of occurrence
of diabetes among psychiatric inpatients (OR
2.86, 95% CI 1.57–5.2) [22], and Lambert et al.
found that any combination of SGAs and FGAs
was associated with an increased likelihood of
occurrence of diabetes in patients with
schizophrenia (OR 1.6, 95% CI 1.3–1.9) [24].
However, three additional studies did not find
an association between antipsychotic polyther-
apy and the occurrence of diabetes compared to
untreated patients [14, 17] or patients receiving
FGAs [25].
Potential Determinants of Occurrence
of Metabolic Disorders
Twenty studies reported the results of potential
determinants other than the specific
Fig. 5 a Risk of dyslipidemia in individuals who received
second-generation antipsychotics (binary outcomes). Note:
a study conducted by Jerrell et al. [46] reported that
risperidone, olanzapine, quetiapine, ziprasidone, and arip-
iprazole were not associated with an increased likelihood of
dyslipidemia, but the authors did not report the specific
results for these SGAs. b Risk of dyslipidemia in
individuals who received second-generation antipsychotics
(time-to-event outcomes). APS antipsychotic, Ari aripipra-
zole, CI confidence interval, Clo clozapine, FGAs first-
generation antipsychotics, HR hazard ratio, Ola olanzap-
ine, OR odds ratio, Que quetiapine, Ris risperidone, RR
relative risk, SGAs second-generation antipsychotics, Zip
ziprasidone
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antipsychotic of the occurrence of diabetes
(Supplementary Table 5) [14–17, 19–28, 30,
31, 33, 36–38]. The factors most frequently
reported as being associated with the occur-
rence of diabetes were age [14–16, 21, 36–38],
nonwhite race [15, 21, 24], length of exposure
[16, 17, 25, 33], obesity/body mass index (BMI)
[15, 16, 19, 20, 23, 26, 27, 31], hypertension
[19, 20, 26, 27, 36], dyslipidemia
[20, 21, 26, 36, 37], and treatment with con-
comitant medications, such as beta-blockers
[15–17, 24, 31]; thiazides [15, 16, 24, 31];
angiotensin-converting enzyme inhibitors [24];
antihypertensives [38]; lipid-lowering drugs
[38]; specific lipid-lowering drugs, including
fibrates [31] and statins [15, 31]; and selective
serotonin reuptake inhibitors (SSRIs) [15, 24].
Regarding the type of psychiatric diagnosis,
some studies found an increased risk of occur-
rence of diabetes for those with schizophrenia
[16, 30, 31], bipolar disorder [30], and post-
traumatic stress disorder [30], while others
found that major affective disorders were asso-
ciated with a reduced risk of occurrence of dia-
betes [17]; finally, some studies did not find that
the type of diagnosis was a factor associated
with the occurrence of diabetes [14, 20, 23].
When psychiatric diagnosis was evaluated as a
comorbidity, an increased risk of diabetes was
reported for impulse control disorders [26] and
substance use disorders [15, 27], while the
presence of a comorbid bipolar disorder was
associated with a reduced risk of diabetes in one
study [33]. We did not find information on the
potential determinants of hyperglycemia com-
plications; however, in a bivariate analysis, the
incidence of these complications was higher in
patients aged 66 years or older than in those
aged 18–65 years, overall and for any antipsy-
chotic [41]. Regarding weight gain, Farwell et al.
Fig. 6 a Risk of hypertension in individuals who received
second-generation antipsychotics (binary outcomes). Jerrell
and McIntyre [46] reported that risperidone, olanzapine,
quetiapine, and aripiprazole were not associated with an
increased likelihood of hypertension, but they did not
report the specific results for these SGAs. b Risk of
hypertension in individuals who received second-genera-
tion antipsychotics (time-to-event outcomes). APS antipsy-
chotic, CI confidence interval, Clo clozapine, FGAs first-
generation antipsychotics, HR hazard ratio, Ola olanzap-
ine, OR odds ratio, Que quetiapine, SGAs second-gener-
ation antipsychotics, Zip ziprasidone
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[23] reported that baseline weight was associ-
ated with a reduced risk of weight gain of at
least 7% (OR 0.99, 95% CI 0.96–0.99).
The potential determinants of the occur-
rence of dyslipidemia were reported in three
studies (Supplementary Table 6) [36, 43, 44].
Age [36, 43], the presence of diabetes
[36, 43, 44], and the presence of hypertension
[36, 43] were reported to be associated with an
increased likelihood of developing
dyslipidemia.
Studies reporting the potential determinants
of the occurrence of hypertension are shown in
Supplementary Table 7. Regarding the potential
determinants of the occurrence of hyperten-
sion, two studies reported that it increased as
age increased [36, 47], and the results regarding
sex were conflicting, with one study reporting
an increased likelihood of developing hyper-
tension in women (OR 1.38, 95% CI 1.09–1.74)
[42] and another study reporting an increased
likelihood in men (HR 1.24, 95% CI 1.01–1.53)
[47]. One study reported that the presence of
diabetes or dyslipidemia was associated with an
increased likelihood of hypertension [36].
Fig. 7 Risk of metabolic disorders in patients aged
65 years or older who received second-generation antipsy-
chotics (binary outcomes). Lipscombe et al. [51] reported
results separately for patients treated with insulin (a),
patients who received oral antidiabetic agents (b), and
patients who did not receive antidiabetics (c). APS
antipsychotic, CI confidence interval, IN insulin, OADs
oral antidiabetic drugs, Ola olanzapine, OR odds ratio, Que
quetiapine, Ris risperidone, RR relative risk, SGAs second-
generation antipsychotics
Fig. 8 Risk of metabolic disorders in patients aged
65 years or older who received second-generation antipsy-
chotics (time-to-event outcomes). CI confidence interval,
Clo clozapine, HR hazard ratio, Ola olanzapine, OR odds
ratio, Que quetiapine, Ris risperidone
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DISCUSSION
Randomized controlled trials provide robust
evidence of the efficacy of antipsychotics and
important information on their tolerability and
safety. However, they require selected samples
for isolating the drug effects [53]. In addition,
these explanatory trials, usually performed for
registrational purposes, are focused on the effi-
cacy of drugs and with short-term duration.
Therefore, they are not the best option for
evaluating infrequent outcomes (e.g., diabetic
ketoacidosis) or those that require longer
latency periods such it is the case of most
metabolic side effects. Therefore, this informa-
tion should be complemented with the results
of long-term—preferably pragmatic—trials or
observational studies that better resemble clin-
ical practice.
According to our review, diabetes is the most
frequently studied metabolic disorder under
real-world conditions using a population-based
design; this is consistent with the long-standing
interest in the relationship between car-
diometabolic disorders, especially diabetes, and
psychosis [54]. The results of this review con-
sistently indicate that clozapine and olanzapine
are associated with an increased likelihood of
developing diabetes in clinical practice. The
results for risperidone and quetiapine are
mixed, although most studies analyzing time-
to-event data indicate that both of these SGAs
are associated with an increased likelihood of
developing diabetes compared to FGA. Infor-
mation on ziprasidone and aripiprazole is scant.
Ziprasidone was consistently reported to not be
associated with an increased likelihood of
occurrence of diabetes in the four studies ana-
lyzing this outcome compared to patients who
did not receive antipsychotics [15] and patients
who received FGAs [26, 27, 31]. Only three
studies reported data on the risk of diabetes
with aripiprazole, showing no increased likeli-
hood of developing diabetes compared to FGA
in one study [31]; compared to antipsychotic-
naı̈ve patients, a study showed a reduced like-
lihood of developing diabetes with aripiprazole
using a binary outcome [38], while another
study showed an increased likelihood using a
time-to-event outcome [39]. Head-to-head
comparisons among the SGAs are limited to
three studies [32–34], which indicated no dif-
ference in two of the paired comparisons
[32, 33], including comparisons of aripiprazole
with risperidone, olanzapine, quetiapine, and
ziprasidone in a study using propensity scores
[32]; however, a third comparison showed a
slightly increased risk of occurrence of diabetes
with olanzapine compared to risperidone [34].
We are not aware of any prior systematic
reviews of RCTs evaluating the risk of diabetes
with SGAs; however, our findings are fairly
consistent with the results of systematic reviews
evaluating changes in glucose levels. A recent
network meta-analysis compared the effects of
18 antipsychotics on several metabolic param-
eters from 100 RCTs with a median treatment
duration of 6 weeks [8]. The 37 studies that
evaluated changes in fasting glucose indicated
that clozapine and olanzapine were associated
with greater increases in serum glucose con-
centration, while ziprasidone was associated
with the lowest increase [8]. The authors did not
find strong evidence of changes in serum glu-
cose concentration with risperidone, quetiap-
ine, ziprasidone, or aripiprazole [8]. In a
previous network meta-analysis evaluating
changes in glucose levels from baseline that
included 47 randomized trials, the authors
found that among the antipsychotics included
in our review, only olanzapine was associated
with a significant increase in glucose compared
to placebo and only ziprasidone and risperidone
were associated with significantly better results
than olanzapine; when ranked using the surface
under the cumulative ranking values, ziprasi-
done was ranked as the best and clozapine and
olanzapine as the worst antipsychotics regard-
ing their impact on serum glucose levels [55].
Yu et al. [56], in a meta-analysis of 14 studies in
Chinese patients, found a higher likelihood of
insulin resistance with olanzapine than with
risperidone, ziprasidone, or aripiprazole.
Another meta-analysis of studies conducted in
healthy volunteers suggested that the occur-
rence of insulin resistance depends on treat-
ment length [57], reinforcing the need for long-
term studies on antipsychotic-induced meta-
bolic disorders.
Adv Ther
Although the information is very limited,
two studies indicated that SGAs might have a
differential effect on the risk of ketoacidosis,
with clozapine and olanzapine associated with
an increased risk compared to FGAs, and que-
tiapine and risperidone showing different
effects depending on age (i.e., a longer time to
the occurrence of hyperglycemic emergencies
[i.e., hospitalizations because of hyperglycemia,
diabetic ketoacidosis, or hyperglycemic hyper-
osmolar state] with quetiapine compared to
risperidone in elderly patients but not in
younger adults). Two studies suggested that
SGAs are associated with an increased likeli-
hood of occurrence of hyperglycemic emer-
gencies in elderly patients [51, 52], regardless of
whether they are treated with antidiabetics [51].
A systematic review evaluated case reports or
case series of diabetic ketoacidosis with type 1
diabetes mellitus etiology, but the publication
bias and uncontrolled design inherent in these
reports do not allow us to assess the risk of this
complication with SGAs [58]. However, it is
important to stress the relevance of this poten-
tial complication associated with the use of
SGAs since ketoacidosis has been associated
with a high mortality rate, especially in patients
with significant comorbidities and in elderly
patients [59].
There is a large body of evidence based on
RCTs concerning the risk of obesity or weight
gain associated with SGAs [8, 57, 60]. Notably,
we found only one study that evaluated obesity
and two studies that evaluated weight gain.
Although it is only speculative, we believe that
this gap in information from population-based
studies could be related to the lack of or poor
information about this topic in administrative
databases. Most recent meta-analyses of short-
term RCTs show that there are important dif-
ferences among various SGAs in regard to the
degree of weight gain or the risk of clinically
relevant weight gain [8, 60, 61]. Although more
limited because of the small number of studies,
the results from long-term RCTs support these
differences [62].
The few studies evaluating antipsychotic-in-
duced dyslipidemia included in our review
suggest that aripiprazole is not associated with
an increased risk of this metabolic effect, while
clozapine is, with the remaining antipsychotics
showing mixed results. The results of a meta-
analysis of short-term RCTs show that among
the antipsychotics included in our review,
risperidone, ziprasidone, and aripiprazole were
not associated with deleterious effects on lipid
parameters, while clozapine, olanzapine, and
quetiapine were associated with increases in
total cholesterol and triglycerides, and olanza-
pine and quetiapine were associated with
increases in low density lipoprotein (LDL)
cholesterol [8]. A recently published random-
ized short-term comparison of seven antipsy-
chotics that included risperidone, olanzapine,
quetiapine, ziprasidone, and aripiprazole
showed that all of these antipsychotics were
associated with significant increases in triglyc-
erides and that risperidone, olanzapine, and
quetiapine were also associated with significant
increases in LDL cholesterol [63]. When evalu-
ated as a change from baseline in the diagnosis
of hyperlipidemia, ziprasidone remained
unchanged, risperidone showed an increase in
the proportion of patients with that diagnosis
but was not statistically significant, and arip-
iprazole and, to a greater extent, olanzapine and
quetiapine showed a statistically significant
increase in the proportion of patients with
hyperlipidemia at the end of the follow-up [63].
More long-term studies are needed on SGAs to
further clarify their impact on lipid parameters.
Although six studies evaluated the potential
association between SGAs and the occurrence of
hypertension, no confirmatory evidence can be
drawn from them. It appears that SGAs are
associated with an increased likelihood of
hypertension, and among the individual agents,
in two studies, ziprasidone was associated with
an almost two-fold increase in the likelihood of
developing hypertension compared to FGA
[42, 46]. However, these studies of ziprasidone
were conducted by the same research group
using the same database and therefore these
findings require replication. The limited infor-
mation from randomized comparisons is not
consistent. The short-term randomized head-to-
head comparison of seven antipsychotics men-
tioned above showed no significant changes in
blood pressure with any of the antipsychotics
studied [63]. However, a secondary analysis of
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the 3-month results from the Clinical Antipsy-
chotics Trials of Intervention Effectiveness
(CATIE) found that in patients with baseline
systolic blood pressure (SBP) above the median
(122 mmHg), all of the antipsychotics studied
showed a decrease in SBP, while in patients with
SBP below the median, SBP among ziprasidone-
treated patients increased to a greater extent
than among those treated with perphenazine
(? 8.6 mmHg vs. ? 4.2 mmHg, p = 0.005) [64].
The potential determinants of the occur-
rence of diabetes found in our review included
age, nonwhite race, obesity/BMI, hypertension,
dyslipidemia, and treatment concomitant drugs
such as antihypertensives, lipid-lowering drugs,
and SSRIs; these factors are consistent with
those reported in the literature for the general
population [65–67]. However, it is important to
stress that, probably because of the limitations
of the information included in administrative
databases, the studies included in this review
did not evaluate many well-demonstrated
nongenetic factors of type 2 diabetes mellitus,
such as psychosocial, lifestyle, and dietary fac-
tors. Therefore, our picture of the risk factors for
antipsychotic-induced diabetes is incomplete.
Regarding antipsychotic treatment, several of
the studies included in this review found that
the risk of diabetes increases with the length of
exposure. In our view, this finding is important,
because among other implications, it reinforces
the limitations of short-term pivotal studies on
antipsychotics for establishing the metabolic
profile of antipsychotics and the need for the
continuous monitoring of metabolic parame-
ters in patients who receive treatment with
antipsychotics. Regarding the latter, despite the
availability of recommendations for monitoring
the physical health of patients with severe
mental disorders, adherence to those recom-
mendations is far from optimal [68]. Although
the information on potential determinants of
hyperlipidemia and hypertension is very lim-
ited, another important issue is that all of these
metabolic disorders seem potential factors
associated with the development of the other
metabolic disorders.
In addition to the other limitations men-
tioned above, the literature on the metabolic
adverse effects of second-generation
antipsychotics has some other important limi-
tations. The most common comparator in the
studies included in this review was FGAs as a
group, and the risk of metabolic side effects
differs from one FGA to another. We did not
find any population-based study reporting data
on metabolic adverse events of long-acting
injectable SGAs. Long-acting antipsychotics are
associated with an increased adherence com-
pared to oral antipsychotics [69], and conse-
quently to a greater exposure to these drugs that
in turn could be associated with a greater risk of
metabolic side effects. Supporting this hypoth-
esis, it has been reported that, compared to oral
SGAs, long-acting injectable SGAs are associated
with a greater risk of some adverse events, such
as extrapyramidal and prolactin-related symp-
toms [70, 71], and some metabolic disorders,
such as changes in LDL cholesterol [72]. Despite
the benefits of long-acting injectable SGAs [73],
it is important to know the metabolic risk
associated with these formulations to facilitate
the rational use of these compounds.
On the basis of the results of a meta-analysis
of RCTs, the SGAs associated with better meta-
bolic profiles are, in alphabetical order, arip-
iprazole, brexpiprazole, cariprazine, lurasidone,
and ziprasidone [8]. However, according to our
results, the worst metabolically characterized
SGAs are ziprasidone and aripiprazole, and we
did not find any population-based studies eval-
uating brexpiprazole, cariprazine, or lurasidone.
Finally, although our evaluation of the
quality of the studies using the Newcastle–Ot-
tawa scale suggests that the overall quality of
the studies is fairly good, it is important to stress
that only five of the studies included in this
review used an adequate methodology to try to
control for confounding by indication (e.g.,
propensity scores). Confounding by indication
is a significant threat to the internal validity of
observational studies of interventions [74],
including the study of antipsychotic-induced
metabolic disorders [75], and its potential
impact was recognized by several of the authors
of the studies included in this review
[11, 20, 22, 39].
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CONCLUSIONS
Our results indicated that although there are
relevant differences among SGAs concerning
the risk of metabolic disorders, with ziprasidone
and aripiprazole at one extreme of the risk
continuum and olanzapine and clozapine at the
other, it appears that none of the SGAs included
in our review are fully devoid of these distur-
bances. This is a relevant finding since recent
data from 14 developed countries indicates that
olanzapine is the second most frequently pre-
scribed antipsychotic in adults [76], and cloza-
pine is increasingly prescribed [77] in addition
to being the only indicated and evidence-based
treatment option for treatment-resistant
schizophrenia [78]. Importantly, our results
suggest that the presence of a particular meta-
bolic disorder acts as a risk factor for the
occurrence of other metabolic disorders. This
finding reinforces the recommendation from
psychiatric clinical practice guidelines that in
any patient with a metabolic disorder, it is also
important to assess other contributors to meta-
bolic syndrome [7]. In addition, as recom-
mended in the general guidelines for the
management of individual metabolic condi-
tions in the general population, the manage-
ment of these complications of antipsychotic
treatment requires an integrated approach since
the presence of one disorder may affect the
management of the other [79–81]. However,
important gaps in the routine screening of
metabolic disorders are found in clinical prac-
tice [82]. The barriers associated with these gaps
include healthcare system-related factors such
as the fragmentation of care and time and
resources constraints, and patient-related fac-
tors such as disability resulting from mental
health conditions, knowledge, and skills of the
patients [83].
Despite almost 20 years of real-world
research using population-based studies, many
gaps in the understanding of the metabolic side
effects of SGAs still exist. Future research should
help to characterize the metabolic profile of the
increasingly used long-acting injectable an-
tipsychotics and of new oral SGAs identified in
RCTs that have a better metabolic profile, such
as brexpiprazole, cariprazine, or lurasidone, and
to ascertain to what extent and how antipsy-
chotic-induced metabolic disorders contribute
to the burden of disease.
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